A 'birds eye view on the current status and potential benefits of blood biomarkers for Parkinsons disease

Biomarkers in Medicine

Volumn 8, Issue 2, 2014, Pages 225-227

  Mielke, Michelle M ^a   Maetzler, Walter ^b,c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

biomarker; blood; diagnosis; Parkinsons disease; prediction

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR;

BLOOD; CEREBROSPINAL FLUID; DISEASE COURSE; EDITORIAL; HUMAN; METABOLISM; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; HUMANS; PARKINSON DISEASE;

EID: 84894299915     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.139     Document Type: Review

References (19)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
2. Gerlach M, Maetzler W, Broich K et al. Biomarker candidates of neurodegeneration in Parkinsons disease for the evaluation of disease-modifying therapeutics. J. Neural Transm. 119(1), 39-52 (2012).
3. Martinez-Martin P, Schapira AH, Stocchi F et al. Prevalence of nonmotor symptoms in Parkinsons disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov. Disord. 22(11), 1623-1629 (2007).
4. Maetzler W. Why do nondopaminergic features in Parkinson disease matter? Neurology doi:10.1212/ wnl.0000000000000095 (2014) (Epub ahead of print).
5. Lebouvier T, Neunlist M, Bruley des Varannes S et al. Colonic biopsies to assess the neuropathology of Parkinsons disease and its relationship with symptoms. PLoS ONE 5(9), e12728 (2010).
6. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10(3), 230-240 (2011).
7. Wang Y, Shi M, Chung KA et al. Phosphorylated alpha-synuclein in Parkinsons disease. Sci. Transl. Med. 4(121), 121ra120 (2012).
8. Bruggink KA, Kuiperij HB, Ekholm- Pettersson F, Verbeek MM. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 77(5), 510 (2011).
9. Shi M, Bradner J, Hancock AM et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 69(3), 570-580 (2011).
10. Waragai M, Nakai M, Wei J et al. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinsons disease. Neurosci. Lett. 425(1), 18-22 (2007).
11. Qiang JK, Wong YC, Siderowf A et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann. Neurol. 74(1), 119-127 (2013).
12. Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch. Neurol. 69(3), 380-384 (2012).
13. Bogdanov M, Matson WR, Wang L et al. Metabolomic profiling to develop blood biomarkers for Parkinsons disease. Brain 131(Pt 2), 389-396 (2008).
14. Chen-Plotkin AS, Hu WT, Siderowf A et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann. Neurol. 69(4), 655-663 (2011).
15. Iwakura Y, Piao YS, Mizuno M et al. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinsons disease and its model: neurotrophic implication in nigrostriatal neurons. J. Neurochem. 93(4), 974-983 (2005).
16. Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinsons disease. Brain 132(Pt 7), 1783-1794 (2009).
17. Brockmann K, Srulijes K, Hauser AK et al. GBA-Associated PD presents with nonmotor characteristics. Neurology 77(3), 276-280 (2011).
18. Mielke MM, Maetzler W, Haughey NJ et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinsons disease and associated with cognitive impairment: a pilot study. PLoS ONE 8(9), e73094 (2013).
19. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95(4), 629-635 (2011).